Additional file 2: Table S1. of Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2â breast cancer that had progressed during or after prior endocrine therapy

Musolino, Antonino; Campone, Mario; Neven, Patrick; Denduluri, Neelima; Barrios, Carlos; Cortes, Javier; Blackwell, Kimberly; Soliman, Hatem; Kahan, Zsuzsanna; Bonnefoi, HervĂŠ; Squires, Matthew; Zhang, Yong; Deudon, Stephanie; Shi, Michael; AndrĂŠ, Fabrice

doi:10.6084/m9.figshare.c.3688210_D2.v1

13058_2017_807_MOESM2_ESM.docx (17.45 kB)

Additional file 2: Table S1. of Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2â breast cancer that had progressed during or after prior endocrine therapy

journal contribution

posted on 2017-02-10, 05:00 authored by Antonino Musolino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos Barrios, Javier Cortes, Kimberly Blackwell, Hatem Soliman, Zsuzsanna Kahan, HervĂŠ Bonnefoi, Matthew Squires, Yong Zhang, Stephanie Deudon, Michael Shi, Fabrice AndrĂŠ

Dose changes and dose delays by treatment arm. Table S2. Adverse events leading to study drug discontinuation regardless of study drug relationship. Table S3. Study center. (DOCX 17Â kb)

Funding

Novartis Pharmaceuticals Corporation

History

Usage metrics

Keywords

Dovitinib TKI285 Fulvestrant FGF FGFR Breast cancer Endocrine resistance

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC